Search

Your search keyword '"Siri, Chiara"' showing total 196 results
Start Over Author "Siri, Chiara"
196 results on '"Siri, Chiara"'

2. Optimal MMSE and MoCA cutoffs for cognitive diagnoses in Parkinson's disease: A data-driven decision tree model

Author

Fiorenzato, Eleonora, Cauzzo, Simone, Weis, Luca, Garon, Michela, Pistonesi, Francesca, Cianci, Valeria, Nasi, Maria Laura, Vianello, Francesca, Zecchinelli, Anna Lena, Pezzoli, Gianni, Reali, Elisa, Pozzi, Beatrice, Isaias, Ioannis Ugo, Siri, Chiara, Santangelo, Gabriella, Cuoco, Sofia, Barone, Paolo, Antonini, Angelo, and Biundo, Roberta

Published
2024
Full Text
View/download PDF

3. Can we add whey protein supplementation in patients with Parkinson's disease without interfering with levodopa response?

Author

Pinelli, Giovanna, Siri, Chiara, Ranghetti, Alessandra, Cereda, Viviana, Maestri, Roberto, and Canesi, Margherita

Subjects
*PARKINSON'S disease, *DIETARY proteins, *MUSCLE mass, *WHEY proteins, *DIETARY supplements
Abstract

Objective: The main endpoint of the study was to evaluate if a daily intake of whey protein-based dietary supplement causes a worse response to levodopa in people with Parkinson's Disease (PWPD) Background: In PWPD, the competition between large neutral aminoacids and levodopa at intestinal absorption level may interfere with dopaminergic therapy's (DRT) effect; therefore, protein redistribution dietary regimen has been suggested. Many dietary supplementations are available to help people in balancing the protein intake and overcoming muscle mass loss. However, most of the products contain protein and could potentially affect levodopa action in PWPD. Methods: We performed a randomised single blind monocentric study on PWPD admitted in the rehabilitative unit for a 4-week multidisciplined intensive aerobic rehabilitation treatment. All patients received a standard protein redistribution dietary regimen plus a whey protein-based oral formula (N = 26) or Magnesium (N = 25) twice daily for 28 days. Neurological assessment and physical evaluation were conducted before (T0) and after (T1) rehabilitative treatment; DRT was recorded T0 and T1 as well. The delta of changes within groups in neurological (UPDRS III) and physical (TUG, 6 MW) evaluation scales was compared between groups. Results: Groups were comparable at baseline in clinical and demographic data; at T1, both groups showed a decrease in UPDRS III, TUG and 6 MWT and no differences between deltas were found. DRT remained stable in both groups. Conclusions: Our results show that whey protein supplementation does not interfere with DRT's efficacy and can be used in PWPD who need a protein supplementation without restrictions in intake hours. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

4. Long-Term Impact of Deep Brain Stimulation in Parkinson's Disease: Does It Affect Rehabilitation Outcomes?

Author

Canesi, Margherita, Lippi, Lorenzo, Rivaroli, Simone, Vavassori, Daniele, Trenti, Marta, Sartorio, Francesco, Meucci, Nicoletta, de Sire, Alessandro, Siri, Chiara, and Invernizzi, Marco

Subjects
DEEP brain stimulation, SUBTHALAMIC nucleus, PARKINSON'S disease, REHABILITATION, AEROBIC exercises, MEDICAL rehabilitation
Abstract

Background and Objectives: Although the growing literature is now focusing on the long-term effects of Deep Brain Stimulation (DBS) in Parkinson's disease (PD), there is still a large gap of knowledge about its long-term implications in rehabilitation. Therefore, this study aimed at investigating the effects of rehabilitation in PD patients years after DBS implantation. Materials and Methods: This retrospective case–control study analyzed records from Moriggia-Pelascini Hospital, Italy from September 2022 to January 2024. Data of PD patients (n = 47) with (DBS group, n = 22) and without (control group, n = 25) DBS were considered. All study participants underwent a daily rehabilitation program lasting four weeks, including warm-up, aerobic exercises, strength training, postural exercises, and proprioceptive activities. The outcomes assessed were the Unified Parkinson's Disease Rating Scale (UPDRS), Berg Balance Scale (BBS), Timed Up and Go (TUG), 6 Min Walk Test (6MWT), and Self-Assessment Parkinson Disease Scale (SPDDS). Results: DBS group showed significant improvements in terms of all outcome measures after the rehabilitation intervention (UPDRS III: −7.0 (−11.5 to −1.0); p = 0.001; UPDRS I II IV: −12.0 (−19.0 to −4.5); p = 0.001; BBS: 7.0 (3.8 to 10.3); p < 0.001; TUG (s): −2.8 (−5.7 to −1.1); p < 0.001; SPDDS: −8 (−13.0 to −4.0); p < 0.001; 6MWT (m): 81 (37.3 to 132.3); p < 0.001). No differences were reported in the between-group analysis (p: NS). Conclusions: This study emphasizes positive rehabilitation effects on PD patients irrespective of DBS status. Further research is essential to elucidate long-term effects of DBS on rehabilitation outcomes of PD patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

10. Dementia in Parkinson's disease: Is male gender a risk factor?

Author

Cereda, Emanuele, Cilia, Roberto, Klersy, Catherine, Siri, Chiara, Pozzi, Beatrice, Reali, Elisa, Colombo, Aurora, Zecchinelli, Anna Lena, Mariani, Claudio Bruno, Tesei, Silvana, Canesi, Margherita, Sacilotto, Giorgio, Meucci, Nicoletta, Zini, Michela, Isaias, Ioannis Ugo, Barichella, Michela, Cassani, Erica, Goldwurm, Stefano, and Pezzoli, Gianni

Published
2016
Full Text
View/download PDF

14. Penetrance estimate of LRRK2 p.G2019S mutation in individuals of non‐Ashkenazi Jewish ancestry

Author

Lee, Annie J., Wang, Yuanjia, Alcalay, Roy N., Mejia‐Santana, Helen, Saunders‐Pullman, Rachel, Bressman, Susan, Corvol, Jean‐Christophe, Brice, Alexis, Lesage, Suzanne, Mangone, Graziella, Tolosa, Eduardo, Pont‐Sunyer, Claustre, Vilas, Dolores, Schüle, Birgitt, Kausar, Farah, Foroud, Tatiana, Berg, Daniela, Brockmann, Kathrin, Goldwurm, Stefano, Siri, Chiara, Asselta, Rosanna, Ruiz‐Martinez, Javier, Mondragón, Elisabet, Marras, Connie, Ghate, Taneera, Giladi, Nir, Mirelman, Anat, and Marder, Karen

Published
2017
Full Text
View/download PDF

15. Cognitive and Neuropsychiatric Features of COVID-19 Patients After Hospital Dismission: An Italian Sample

Author

Cian, Veronica, De Laurenzis, Alessandro, Siri, Chiara, Gusmeroli, Anna, and Canesi, Margherita

Subjects
General Psychology
Abstract

Background and AimsRecent studies suggest cognitive, emotional, and behavioral impairments occur in patients after SARS-CoV-2 infection. However, studies are limited to case reports or case series and, to our knowledge, few of them have control groups. This study aims to assess the prevalence of neuropsychological and neuropsychiatric impairment in patients after hospitalization.MethodsWe enrolled 29 COVID+ patients (M/F: 17/12; age 58.41 ± 10.00 years; education 11.07 ± 3.77 years, 2 left handers) who needed hospitalization but no IC, about 20 days post-dismission, and 29 COVID− healthy matched controls. Neuropsychological and neuropsychiatric assessments were conducted via teleneuropsychology using the following tests: MMSE, CPM47, RAVLT, CDT, Digit-Span Forward/Backward, Verbal fluencies; BDI-II, STAI. People with previous reported cognitive impairment and neurological or psychiatric conditions were excluded. Clinical and demographics were collected. Comparison between groups was conducted using parametric or non-parametric tests according to data distribution (T-test, Mann Withney-U test; Chi-square goodness of fit). Within COVID+ group, we also evaluated the correlation between the cognitive and behavioral assessment scores and clinical variables collected.ResultsAmong COVID+, 62% had at least one pathological test (vs. 13% in COVID−; p = 0.000) and significantly worst performances than COVID− in RAVLT learning (42.55 ± 10.44 vs. 47.9 ± 8.29, p = 0.035), RAVLT recall (8.79 ± 3.13 vs. 10.38 ± 2.19, p = 0.03), and recognition (13.69 ± 1.47 vs. 14.52 ± 0.63, p = 0.07). STAI II was higher in COVID− (32.69 ± 7.66 vs. 39.14 ± 7.7, p = 0.002). Chi-square on dichotomous values (normal/pathological) showed a significant difference between groups in Digit backward test (pathological 7/29 COVID+ vs. 0/29 COVID−; p = 0.005).ConclusionsPatients COVID+ assessed by teleneuropsychology showed a vulnerability in some memory and executive functions (working memory, learning, delayed recall, and recognition). Intriguingly, anxiety was higher in the control group. Our findings therefore confirm the impact of COVID-19 on cognition even in patients who did not need IC. Follow-up is needed to evaluate the evolution of COVID-19-related cognitive deficit.Clinical Trial Registration[ClinicalTrials.gov], identifier [NCT05143320].

Published
2022

24. The Hopkins Symptom Checklist (SCL-90-R): A Patient-Reported Outcome Measure in Parkinson's Disease.

Author

Carrozzino, Danilo, Christensen, Kaj Sparle, Patierno, Chiara, Siri, Chiara, Zecchinelli, Anna, Pezzoli, Gianni, and Cosci, Fiammetta

Subjects
PARKINSON'S disease, PSYCHOLOGICAL distress, SYMPTOMS, MEDICAL screening, TEST validity, MOVEMENT disorders
Abstract

Objective : This is the first study applying Clinimetric Patient-Reported Outcome Measures (CLIPROM) criteria to evaluate the construct validity, sensitivity, and clinical utility of the SCL-90-R in patients with Parkinson's disease (PD). Methods : A Rasch analysis was conducted using a sample of 488 PD outpatients. Results: Testing for dimensionality revealed that less than 5% of t -tests were significant, indicating that the SCL-90-R subscales entailed the property of construct validity. As to the total score, a Person Separation Reliability Index of.96 was found. Conclusions: The SCL-90-R total score is a sensitive screening measure that can be used not only to differentiate healthy stress reactions from symptoms of psychological distress but also to detect PD patients with an increased risk for psychiatric complications. As to the subscales, the brief versions that did not include misfitting items should be used to assess the severity of specific symptoms of psychological distress affecting PD patients. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

26. LRRK2 G2019S mutation and Parkinson's disease: A clinical, neuropsychological and neuropsychiatric study in a large Italian sample

Author

Goldwurm, Stefano, Zini, Michela, Di Fonzo, Alessio, De Gaspari, Danilo, Siri, Chiara, Simons, Erik J., van Doeselaar, Marina, Tesei, Silvana, Antonini, Angelo, Canesi, Margherita, Zecchinelli, Anna, Mariani, Claudio, Meucci, Nicoletta, Sacilotto, Giorgio, Cilia, Roberto, Isaias, Ioannis U., Bonetti, A., Sironi, Francesca, Ricca, Sara, Oostra, Ben A., Bonifati, Vincenzo, and Pezzoli, Gianni

Published
2006
Full Text
View/download PDF

32. Pathological Gambling in Parkinson's disease: autonomic measures supporting impaired decision-making

Author

Angioletti, Laura, Siri, Chiara, Meucci, Nicoletta, Pezzoli, Gianni, Balconi, Michela, Angioletti Laura (ORCID:0000-0002-3027-2272), Balconi Michela (ORCID:0000-0002-8634-1951), Angioletti, Laura, Siri, Chiara, Meucci, Nicoletta, Pezzoli, Gianni, Balconi, Michela, Angioletti Laura (ORCID:0000-0002-3027-2272), and Balconi Michela (ORCID:0000-0002-8634-1951)

Abstract

According to the somatic marker hypothesis, autonomic measures and arousal modulation can reveal a difference in subgroups of patients developing impaired decision-making because of addictions. Previously, pathological gambling (PG) and Parkinson's disease (PD) have been associated with differential arousal levels during gambling behavior. However, no research considered the specific autonomic responses of Parkinson's disease patients with pathological gambling and with a previous history of gambling. Thus, this study investigated skin conductance responses (SCRs), skin conductance level (SCL) and heart rate (HR) during the Iowa Gambling Task (IGT) in two groups of PD patients with gambling disorder, active (PD Gamblers; n = 14) or remitted (PD Non-Gamblers; n = 13) and a control group of patients with Parkinson's disease only (n = 13). Anticipatory autonomic responses to disadvantageous decks and advantageous decks during the Iowa Gambling Task were measured for each participant. The PD Gamblers group performed worse than the PD Non-Gamblers and the control groups at the IGT task and exhibited lower SCRs, SCL, and HR during the decision-making processing of cards belonging to disadvantageous decks. The role of autonomic and behavioral measures was considered.

Published
2019

38. Personality traits and cortical activity affect gambling behavior in Parkinson's disease

Author

Balconi, Michela, Siri, Chiara, Meucci, Nicoletta, Pezzoli, Gianni, Angioletti, Laura, Balconi, Michela (ORCID:0000-0002-8634-1951), Angioletti, Laura (ORCID:0000-0002-3027-2272), Balconi, Michela, Siri, Chiara, Meucci, Nicoletta, Pezzoli, Gianni, Angioletti, Laura, Balconi, Michela (ORCID:0000-0002-8634-1951), and Angioletti, Laura (ORCID:0000-0002-3027-2272)

Abstract

Background: Pathological gambling (PG) in Parkinson's disease (PD) manifests as a persistent and uncontrollable gambling behavior, characterized by dysfunctional decision-making and emotional impairment related to high-risk decisions. Objective: The aim of this study was to explore the relationship between personality traits and prefrontal cortex activity in PD patients with or without PG. Methods: Thus, hemodynamic cortical activity measured by functional near-infrared spectroscopy (fNIRS) and Iowa Gambling Task (IGT) performance were recorded in forty-six PD patients, divided into three groups according to their gambling status: PD patients with active gambling behavior (PDG); PD patients who remitted from PG (PDNG); and a control group (CG) composed by patients with PD only. Results: Results indicates that gambling behavior in PD patients is strongly predictive of dysfunctional cognitive strategy; affecting anomalous cortical response with a left hemispheric unbalance in dorsal areas; and it is related to more reward sensitivity than impulsivity personality components. Conclusions: PDG patients differed from PDNG and CG from both behavioral and brain response to decision-making. Overall, these effects confirm a pathological condition related to cognitive and emotional aspects which makes the patients with PGD victims of their dysfunctional behavior.

Published
2018

41. Penetrance estimate of LRRK2 p.G2019S mutation in individuals of non-Ashkenazi Jewish ancestry

Author

Lee, Annie J, Wang, Yuanjia, Tolosa, Eduardo, Pont-Sunyer, Claustre, Vilas, Dolores, Schüle, Birgitt, Kausar, Farah, Foroud, Tatiana, Berg, Daniela, Brockmann, Kathrin, Goldwurm, Stefano, Siri, Chiara, Alcalay, Roy N, Asselta, Rosanna, Ruiz-Martinez, Javier, Mondragón, Elisabet, Marras, Connie, Ghate, Taneera, Giladi, Nir, Mirelman, Anat, Marder, Karen, Fox LRRK2 Cohort Consortium, Michael J., Mejia-Santana, Helen, Saunders-Pullman, Rachel, Bressman, Susan, Corvol, Jean-Christophe, Brice, Alexis, Lesage, Suzanne, and Mangone, Graziella

Subjects
Adult, Male, genetics [Jews], Glycine, genetics [Mutation], Penetrance, Leucine-Rich Repeat Serine-Threonine Protein Kinase-2, Article, Cohort Studies, Gene Frequency, genetics [Parkinson Disease], Serine, Humans, Genetic Predisposition to Disease, ddc:610, genetics [Glycine], Genetic Testing, genetics [Genetic Predisposition to Disease], Aged, Aged, 80 and over, Family Health, genetics [Serine], Parkinson Disease, Middle Aged, Jews, Mutation, genetics [Leucine-Rich Repeat Serine-Threonine Protein Kinase-2], Female, ethnology [Parkinson Disease]
Abstract

Penetrance estimates of the leucine-rich repeat kinase 2 (LRRK2) p.G2019S mutation for PD vary widely (24%-100%). The p.G2019S penetrance in individuals of Ashkenazi Jewish ancestry has been estimated as 25%, adjusted for multiple covariates. It is unknown whether penetrance varies among different ethnic groups. The objective of this study was to estimate the penetrance of p.G2019S in individuals of non-Ashkenazi Jewish ancestry and compare penetrance between Ashkenazi Jews and non-Ashkenazi Jews to age 80.The kin-cohort method was used to estimate penetrance in 474 first-degree relatives of 69 non-Ashkenazi Jewish LRRK2 p.G2019S carrier probands at 8 sites from the Michael J. Fox LRRK2 Cohort Consortium. An identical validated family history interview was administered to assess age at onset of PD, current age, or age at death for relatives in different ethnic groups at each site. Neurological examination and LRRK2 genotype of relatives were included when available.Risk of PD in non-Ashkenazi Jewish relatives who carry a LRRK2 p.G2019S mutation was 42.5% (95% confidence interval [CI]: 26.3%-65.8%) to age 80, which is not significantly higher than the previously estimated 25% (95% CI: 16.7%-34.2%) in Ashkenazi Jewish carrier relatives. The penetrance of PD to age 80 in LRRK2 p.G2019S mutation carrier relatives was significantly higher than the noncarrier relatives, as seen in Ashkenazi Jewish relatives.The similar penetrance of LRRK2 p.G2019S estimated in Ashkenazi Jewish carriers and non-Ashkenazi Jewish carriers confirms that p.G2019S penetrance is 25% to 42.5% at age 80 in all populations analyzed. © 2017 International Parkinson and Movement Disorder Society.

Published
2016
Full Text
View/download PDF

44. Protein-redistribution diet in a case of tyrosine hydroxylase enzyme deficiency

Author

Cassani, Erica, primary, Barichella, Michela, additional, Ferri, Valentina, additional, Pusani, Chiara, additional, Goldwurm, Stefano, additional, Siri, Chiara, additional, Zini, Michela, additional, Zorzi, Giovanna Simonetta, additional, Cereda, Emanuele, additional, Iorio, Laura, additional, Pinelli, Giovanna, additional, Sacilotto, Giorgio, additional, and Pezzoli, Gianni, additional

Published
2017
Full Text
View/download PDF

48. Survival and dementia in GBA‐associated Parkinson's disease: The mutation matters

Author

Cilia, Roberto, primary, Tunesi, Sara, additional, Marotta, Giorgio, additional, Cereda, Emanuele, additional, Siri, Chiara, additional, Tesei, Silvana, additional, Zecchinelli, Anna L., additional, Canesi, Margherita, additional, Mariani, Claudio B., additional, Meucci, Nicoletta, additional, Sacilotto, Giorgio, additional, Zini, Michela, additional, Barichella, Michela, additional, Magnani, Corrado, additional, Duga, Stefano, additional, Asselta, Rosanna, additional, Soldà, Giulia, additional, Seresini, Agostino, additional, Seia, Manuela, additional, Pezzoli, Gianni, additional, and Goldwurm, Stefano, additional

Published
2016
Full Text
View/download PDF

50. Cognitive profile in non-demented GBA-carriers Parkinson's disease patients

Author

Siri, Chiara, primary, Reali, Elisa, additional, Pozzi, Beatrice, additional, Colombo, Aurora, additional, Cilia, Roberto, additional, Canesi, Margherita, additional, Mariani, Claudio Bruno, additional, Meucci, Nicoletta, additional, Sacilotto, Giorgio, additional, Tesei, Silvana, additional, Zecchinelli, Anna Lena, additional, Zini, Michela, additional, Pezzoli, Gianni, additional, and Goldwurm, Stefano, additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results